한글목차

mRNA 플랫폼 세계 시장은 2030년까지 1,202억 달러에 달할 것으로 전망

2023년 1,499억 달러로 추정되는 mRNA 플랫폼 세계 시장은 2030년 1,202억 달러에 달할 것으로 예상되며, 분석 기간인 2023년부터 2030년까지 연평균 -3.1%의 성장률을 기록할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 COVID-19 백신은 CAGR -6.1%를 기록했으며, 분석 기간 종료 시점에 104.7%의 CAGR로 965억 달러에 달할 것으로 예상됩니다.

미국 시장은 675억 달러로 추정, 중국은 CAGR -0.8%로 성장할 것으로 전망

미국의 mRNA 플랫폼 시장 규모는 2023년 675억 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 시장 규모가 138억 달러에 달할 것으로 예상되며, 분석 기간인 2023년부터 2030년까지 연평균 -0.8%의 CAGR을 기록할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 -4.2%와 -5.0%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 -3.8%의 CAGR을 기록할 것으로 예상됩니다.

세계 mRNA 플랫폼 시장 - 주요 동향 및 촉진요인 정리

mRNA 플랫폼은 생명공학 및 제약 분야의 획기적인 혁신으로 등장하여 백신 및 치료제 개발 및 전개 방식에 혁명을 일으켰습니다. mRNA, 즉 메신저 RNA는 세포 내 단백질 합성의 청사진 역할을 하며, 이 기술을 사용하여 세포에 면역 반응을 일으키고 질병을 치료하는 특정 단백질을 생성하도록 지시합니다. Moderna와 Pfizer-BioNTech 등이 개발한 mRNA 기반 COVID-19 백신의 성공은 이 플랫폼이 신속하고 확장 가능한 백신 생산이 가능하다는 것을 보여줍니다. 백신 생산이 가능하다는 것을 보여줍니다. 개발 기간이 수개월에서 수년이 걸리는 기존 백신과 달리, mRNA 백신은 훨씬 더 빠르게 설계 및 생산할 수 있어 신종 감염병 대응에 있어 매우 중요한 도구가 될 수 있습니다.

기술의 발전은 mRNA 플랫폼의 능력과 응용을 크게 향상시켰습니다. 지질 나노입자(LNP) 전달 시스템의 혁신은 mRNA 분자의 안정성과 효율을 향상시켜 세포 내로의 효과적인 전달을 가능하게 했습니다. mRNA 플랫폼의 유연성은 새로운 바이러스 변종이나 다른 질병에 대응하는 백신과 치료제를 신속하게 재설계할 수 있어 정밀의료 분야에서 범용성이 높은 도구로 활용되고 있습니다. 정밀의료의 범용성 높은 도구가 되고 있습니다. 또한, 합성생물학 및 생물정보학의 발전으로 보다 정확하고 효율적인 mRNA 서열 설계가 가능해져 코드화된 단백질의 발현과 효능을 최적화할 수 있게 되었습니다.

mRNA 플랫폼 시장의 성장은 전염병 발생률 증가, mRNA 기술 발전, 생명공학 연구에 대한 막대한 투자 등 여러 요인에 의해 촉진되고 있습니다. 현재 진행 중인 전염병의 위협과 신속하고 효과적인 대응의 필요성은 mRNA 백신의 중요성을 강조하고 이 기술에 대한 수요와 투자를 촉진하고 있습니다. 전달 시스템 개선, 보다 효율적인 제조 공정 등 기술 발전으로 mRNA 기반 제품의 확장성과 효능이 향상되고 있습니다. 또한, 민관 양측의 막대한 투자로 R&D 활동이 가속화되고 새로운 치료 응용 분야가 생겨나면서 시장 잠재력이 확대되고 있으며, mRNA 백신과 치료제에 대한 규제 당국의 지원과 신속한 승인 절차도 이 시장의 빠른 성장에 기여하고 있습니다. 이러한 요인들은 mRNA 플랫폼이 현대 의학에 미치는 변혁적 영향과 다양한 건강 문제를 해결할 수 있는 잠재력을 강조하고 있습니다.

조사 대상 기업 예시(총 96개사)

• AstraZeneca PLC
• Asuragen, Inc.
• Catalent Pharma Solutions
• Altogen Labs
• Arcturus Therapeutics, Inc.
• BioNTech AG
• CRISPR Therapeutics
• Aldevron
• AKESOgen, Inc.
• baseclick GmbH
• chimeron bio
• Acuitas Therapeutics
• Accent Therapeutics
• Accanis Biotech F&E GmbH & Co KG
• Avectas

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 세계 시장 개요
• 경쟁 시나리오
• 주요 기업
• 시장 동향과 성장 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 인도
• 호주
• 뉴질랜드
• 세계 기타 지역
• 중동
• 바레인
• 아프리카
• 남아프리카공화국
• 라틴아메리카
• 브라질
• 멕시코

제4장 경쟁

영문목차

Global mRNA Platform Market to Reach US$120.2 Billion by 2030

The global market for mRNA Platform estimated at US$149.9 Billion in the year 2023, is expected to reach US$120.2 Billion by 2030, growing at a CAGR of -3.1% over the analysis period 2023-2030. Covid-19 Vaccine, one of the segments analyzed in the report, is expected to record a -6.1% CAGR and reach US$96.5 Billion by the end of the analysis period. Growth in the Cancer Vaccine segment is estimated at 104.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$67.5 Billion While China is Forecast to Grow at -0.8% CAGR

The mRNA Platform market in the U.S. is estimated at US$67.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$13.8 Billion by the year 2030 trailing a CAGR of -0.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of -4.2% and -5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately -3.8% CAGR.

Global mRNA Platform Market - Key Trends & Drivers Summarized

The mRNA platform has emerged as a groundbreaking innovation in the field of biotechnology and pharmaceuticals, revolutionizing the way vaccines and therapeutics are developed and deployed. mRNA, or messenger RNA, acts as a blueprint for protein synthesis within cells, and this technology harnesses that mechanism to instruct cells to produce specific proteins that can trigger an immune response or treat diseases. The success of mRNA-based COVID-19 vaccines, developed by companies like Moderna and Pfizer-BioNTech, has showcased the platform's potential for rapid and scalable vaccine production. Unlike traditional vaccines, which often require months or years to develop, mRNA vaccines can be designed and manufactured much more quickly, providing a crucial tool in responding to emerging infectious diseases.

Technological advancements have significantly enhanced the capabilities and applications of the mRNA platform. Innovations in lipid nanoparticle (LNP) delivery systems have improved the stability and efficiency of mRNA molecules, allowing for effective delivery into cells. This has broadened the potential applications of mRNA technology beyond vaccines to include treatments for cancer, genetic disorders, and other diseases. The flexibility of the mRNA platform allows for the rapid redesign of vaccines and therapeutics to address new virus variants or different diseases, making it a versatile tool in precision medicine. Additionally, advancements in synthetic biology and bioinformatics have enabled more precise and efficient mRNA sequence design, optimizing the expression and effectiveness of the encoded proteins.

The growth in the mRNA platform market is driven by several factors, including the increasing incidence of infectious diseases, advancements in mRNA technology, and significant investments in biotechnology research. The ongoing threat of pandemics and the need for swift and effective responses have highlighted the importance of mRNA vaccines, spurring demand and investment in this technology. Technological advancements, such as improved delivery systems and more efficient manufacturing processes, have enhanced the scalability and efficacy of mRNA-based products. Furthermore, substantial investments from both public and private sectors are accelerating research and development activities, leading to new therapeutic applications and expanding the market potential. Regulatory support and expedited approval processes for mRNA vaccines and therapies have also contributed to the rapid growth of this market. These factors collectively underscore the transformative impact of the mRNA platform in modern medicine and its potential to address a wide range of health challenges.

Select Competitors (Total 96 Featured) -

• AstraZeneca PLC
• Asuragen, Inc.
• Catalent Pharma Solutions
• Altogen Labs
• Arcturus Therapeutics, Inc.
• BioNTech AG
• CRISPR Therapeutics
• Aldevron
• AKESOgen, Inc.
• baseclick GmbH
• chimeron bio
• Acuitas Therapeutics
• Accent Therapeutics
• Accanis Biotech F&E GmbH & Co KG
• Avectas

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • mRNA Platform - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • mRNA - A CONCEPTUAL UNDERSTANDING
  • mRNA: A New Approach to Medicine
  • Long Wait & Scientific Breakthroughs
  • mRNA Vaccines - An Introduction
  • With Unparalleled Turnaround Time, mRNA Platform Adds Revolutionary Dimension to Vaccine Development
  • mRNA: Making Cells Act as Vaccine Factory
  • mRNA Vaccines: Advantages
  • mRNA Vaccines: Cons
  • mRNA Vaccine Approvals
  • A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
  • Traditional Vs. mRNA Vaccines: Key Differences
  • Traditional Vs. mRNA Vaccines: The Development Process
  • How mRNA Vaccine Works & Earlier Testing Efforts
  • mRNA Vaccines: Safety Quotient
  • Other Notable Efforts Centered on mRNA Technology
  • Overcoming Challenges
  • As Serious Candidate, mRNA Technology Warrants Attention from Scientific Community
• GLOBAL MARKET OVERVIEW
  • Global mRNA Vaccines Market on a Dynamic Growth Track
  • mRNA Vaccines Could Vanquish Cancer and Other Diseases, Cancer Segment to Make Major Contribution to Global mRNA Vaccines Market
  • The US Holds Leading Position, while Asia-Pacific Exhibits Lucrative Growth in mRNA Vaccines Market
  • Faster, Effective and Cheaper: Adaptability of mRNA Vaccine Unleashes Potential Utility for Developing Nations
  • RECENT MARKET ACTIVITY IN THE COVID-19 VACCINE SPACE
  • Pfizer and BioNTech's COVID-19 Vaccine Receives World's First Authorization
  • UK Clinches the First Position in the World to Approve Pfizer's Vaccine
  • After UK, US Gives Nod to Pfizer's Vaccine
  • EU Approves Pfizer's Vaccine
  • BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
  • Novartis Inks Agreement with Pfizer-BioNtech to Support Covid-19 Vaccine Production
  • FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
  • Moderna's mRNA Vaccine Bags Approval from US FDA
  • Moderna Kick-Starts Inoculation in the US
  • FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
  • Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
  • Recent Market Activity
• COMPETITIVE SCENARIO
  • BioNTech - A Pioneer in mRNA-based Vaccines and Therapies
  • List of BioNTech's mRNA Candidates in Clinical Trials for Cancer
  • Moderna's Ambitious Stride into Vaccine Development: From a Novice to Know All
  • Moderna's mRNA Prophylactic Vaccines
  • mRNA Cancer Vaccines
  • mRNA Intratumoral Immuno-Oncology
  • mRNA Systemic Secreted & Cell Surface Therapeutics
  • mRNA Systemic Intracellular Therapeutics
  • Sanofi Commences Clinical Trials of mRNA vaccine for Covid-19
  • mRNA as Promising Vaccine Technology Entices Startups to Join the Bandwagon
  • Noteworthy Startups Exploiting mRNA Technology
  • Providence Therapeutics
  • pHion Therapeutics
  • eTheRNA immunotherapies & 20Med Therapeutics
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Infectious & Chronic Conditions to Unleash Gains & Help mRNA Vaccines Market Gallop Ahead
  • mRNA Vaccines Development for Other Infectious Diseases and Therapeutic Areas Gains Momentum
  • Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
  • Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
  • Increasing Healthcare Expenditure to Foster Market Growth
  • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
  • Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth
  • Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
  • Regulatory Landscape for mRNA Vaccines
  • Regulatory Pathway Dealing with mRNA Vaccines
  • mRNA Vaccine Patent Scenario
  • The Best Route of Administration for mRNA Vaccines
  • mRNA CANCER VACCINES
  • Introduction
  • Cancer Vaccines Vs. Immunotherapies
  • Clinical Trials of mRNA Encoding Immunostimulants
  • mRNA Vaccines Vs. DNA Vaccines
  • Clinical Trials of mRNA Encoding TAAs
  • mRNA Vaccines Vs. Other Vaccines
  • Clinical Trials of mRNA Vaccines Encoding Neoantigens (Neo-Ag)
  • mRNA Benefits Profile
  • mRNA Vaccines for Covid-19 Pave the Way
  • Challenges
  • Personalized mRNA Vaccine
  • Clinical Overview of mRNA Cancer Vaccines
  • mRNA encoding Immunostimulants
  • mRNA vaccine encoding tumor-associated antigens
  • mRNA vaccine encoding Neoantigen, personalized vaccine
  • mRNA Influenza Vaccines
  • Perpetual Evolution of Influenza Viruses Makes mRNA a Fascinating Vaccine Platform
  • Vaccines Built on mRNA
  • Clinical Trials for mRNA Vaccines
  • mRNA Vaccine as Game Changer for Flu Viruses Eluding Conventional Vaccine Efforts
  • mRNA: A Next-Generation Vaccination Approach
  • Moderna Moves Ahead to Brew Novel mRNA Vaccines for Influenza & Other Viruses
  • COVID-19 Vaccine Technology to Foster Development of Effective Flu Shots
  • mRNA Vaccines Vs. Other Flu Shots
  • mRNA Technology, H/N Spike Proteins & Clinical Trials
  • mRNA Technology: A Suitable Candidate for Universal & Effective Influenza Vaccines
  • Benefits & Limitations of mRNA Vaccines over Traditional Options
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World mRNA Platform Market Analysis of Annual Sales in US$ Million for Years 2022 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for mRNA Platform by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World 7-Year Perspective for mRNA Platform by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Covid-19 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 5: World 7-Year Perspective for Covid-19 Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Cancer Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 7: World 7-Year Perspective for Cancer Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World 7-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • US FDA Gives Nod to Pfizer and Moderna's mRNA Vaccines
  • US Regulators Give Nod to Pfizer-BioNTech COVID-19 Vaccine for Ages 12 to 15
  • Sanofi Joins Hands with Moderna to Produce COVID-19 Vaccines for Global Supply
  • TABLE 10: USA Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 11: USA 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
• CANADA
  • Vaccination Gathers Steam Across Canada
  • Percentage (%) of Population Vaccinated (at least one dose) in Canada by Province/Territory As of May 3, 2021
  • COVID-19 Vaccine Deals in Canada
  • Pfizer Plans to Ramp up COVID-19 Vaccine Supply to Canada from May, 2021
  • Canada Grants Approval to Pfizer's COVID-19 Shot for Use in Children in 12-15 Years Age Group
  • TABLE 12: Canada Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 13: Canada 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
• JAPAN
  • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • COVID-19 Vaccination Programs in Japan Move Forward at Snail's Pace
  • Reasons Responsible for Setback
  • Vaccine Timeline & Availability
  • Japan Demands for Vaccine-Related Data
  • People's Low Trust in Vaccines
  • Japan's Efforts to Develop Indigenous Vaccines
  • Japan to Step Up COVID-19 Immunization Drive to Cover Geriatric Population
  • Japan Inks Deal with Pfizer to Secure 50 Million Additional Doses of COVID-19 Vaccine
  • Japan Pushes Shipments of Pfizer's COVID-19 Shots to Vaccinate Elderly
  • TABLE 14: Japan Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 15: Japan 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
• CHINA
  • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • BioNTech's Shot to Become First Western COVID-19 Vaccine to Secure Authorization in China
  • TABLE 16: China Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 17: China 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
• EUROPE
  • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • EU Urges Nations to Focus on COVID-19 Vaccine Sharing & Export to Beat the Pandemic (May, 2021)
  • COVID-19 Vaccine Drive Gathers Pace in Europe after Initial Glitch
  • EU Approves Pfizer's Vaccine
  • EU Eyes on Milestone Deal to Get 1.8 Billion Doses of Pfizer-BioNTech COVID-19 Vaccine
  • European Agency Makes Changes to Ramp Up Supply & Manufacturing Capacity of Pfizer & Moderna COVID-19 Vaccines
  • BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
  • TABLE 18: Europe Recent Past, Current & Future Analysis for mRNA Platform by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 19: Europe 7-Year Perspective for mRNA Platform by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • TABLE 20: Europe Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Europe 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
• FRANCE
  • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 22: France Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 23: France 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
• GERMANY
  • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 24: Germany Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 25: Germany 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
• ITALY
  • Italy Plans to Produce mRNA Vaccines Domestically
  • TABLE 26: Italy Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Italy 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
• UNITED KINGDOM
  • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Market Analysis
  • UK Wins COVID-19 Vaccine Race with Approval of Pfizer-BioNTech Vaccine
  • Moderna Modifies Supply Contract with UK to Deliver Additional Doses of COVID-19 Vaccine
  • UK's Independent Vaccine Deals
  • TABLE 28: UK Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 29: UK 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
• REST OF EUROPE
  • TABLE 30: Rest of Europe Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 31: Rest of Europe 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
• ASIA-PACIFIC
  • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
• INDIA
  • Pfizer Looks Forward to Make its COVID-19 Vaccine Available in India
• AUSTRALIA
  • Australia to Buy 20 Million Extra Doses of Pfizer COVID-19 Vaccine, Pivoting away from AstraZeneca
• NEW ZEALAND
  • New Zealand Acquires Ultra-Cold Freezers to Store Pfizer's COVID-19 Vaccine
  • TABLE 32: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Asia-Pacific 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
• REST OF WORLD
• THE MIDDLE EAST
• BAHRAIN
  • Bahrain Becomes the Second Country to Offer Emergency Use Approval to Pfizer's Vaccine
• AFRICA
• SOUTH AFRICA
  • New Virus Variant in South Africa Creates a Challenge
  • Highly Infectious COVID-19 Variant Spurs Countries to Impose Travel Ban from South Africa
• LATIN AMERICA
  • Mass COVID-19 Vaccination Campaigns Launched in Latin American Countries
• BRAZIL
  • Brazil Signs Deal to Buy Additional 100 Million Doses from Pfizer/BioNTech
• MEXICO
  • Mexico's Cofepris Approves Emergency Use of Pfizer's COVID-19 Vaccine
  • TABLE 34: Rest of World Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 35: Rest of World 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030

IV. COMPETITION